CervoMed Inc. (CRVO)

CervoMed Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	9.74	7.14	-	-
Revenue Growth (YoY)	36.29%	-	-	-
Cost of Revenue	18.8	8.44	1.34	-
Gross Profit	-9.06	-1.29	-1.34	-
Selling, General & Admin	9.17	6.52	2.14	2.62
Research & Development	-	-	-	2.42
Operating Expenses	9.17	6.52	2.14	5.04
Operating Income	-18.23	-7.81	-3.48	-5.04
Interest Expense	-	-	-0	-0
Interest & Investment Income	1.94	0.22	0.06	0.02
Other Non Operating Income (Expenses)	-0	5.42	-2.39	0.74
EBT Excluding Unusual Items	-16.29	-2.17	-5.8	-4.28
Other Unusual Items	-	-	-	0.15
Pretax Income	-16.29	-2.17	-5.8	-4.14
Net Income	-16.29	-2.17	-5.8	-4.14
Net Income to Common	-16.29	-2.17	-5.8	-4.14
Shares Outstanding (Basic)	8	3	1	5
Shares Outstanding (Diluted)	8	3	1	5
Shares Change (YoY)	203.34%	413.65%	-88.49%	-
EPS (Basic)	-2.02	-0.82	-11.20	-0.92
EPS (Diluted)	-2.02	-0.82	-11.20	-0.92
Gross Margin	-93.04%	-18.11%	-	-
Operating Margin	-187.18%	-109.35%	-	-
Profit Margin	-167.29%	-30.40%	-	-
EBIT	-18.23	-7.81	-3.48	-5.04
EBIT Margin	-187.18%	-109.35%	-	-

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q